[go: up one dir, main page]

HK1248803A1 - Specific biomarker set for non-invasive diagnosis of liver cancer - Google Patents

Specific biomarker set for non-invasive diagnosis of liver cancer

Info

Publication number
HK1248803A1
HK1248803A1 HK18107745.3A HK18107745A HK1248803A1 HK 1248803 A1 HK1248803 A1 HK 1248803A1 HK 18107745 A HK18107745 A HK 18107745A HK 1248803 A1 HK1248803 A1 HK 1248803A1
Authority
HK
Hong Kong
Prior art keywords
liver cancer
specific biomarker
invasive diagnosis
biomarker set
invasive
Prior art date
Application number
HK18107745.3A
Other languages
Chinese (zh)
Inventor
文詠賢
衛鳳文
黃炳鏐
衛智賢
Original Assignee
龍勝發展有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/321,867 external-priority patent/US9506925B2/en
Priority claimed from US14/321,870 external-priority patent/US9885718B2/en
Application filed by 龍勝發展有限公司 filed Critical 龍勝發展有限公司
Publication of HK1248803A1 publication Critical patent/HK1248803A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
HK18107745.3A 2014-07-02 2016-06-13 Specific biomarker set for non-invasive diagnosis of liver cancer HK1248803A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/321,867 US9506925B2 (en) 2014-07-02 2014-07-02 Specific biomarker set for non-invasive diagnosis of liver cancer
US14/321,870 US9885718B2 (en) 2014-07-02 2014-07-02 Specific biomarker set for non-invasive diagnosis of liver cancer

Publications (1)

Publication Number Publication Date
HK1248803A1 true HK1248803A1 (en) 2018-10-19

Family

ID=55019816

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16106781.2A HK1224370A1 (en) 2014-07-02 2016-06-13 Specific biomarker set for non-invasive diagnosis of liver cancer
HK18107745.3A HK1248803A1 (en) 2014-07-02 2016-06-13 Specific biomarker set for non-invasive diagnosis of liver cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK16106781.2A HK1224370A1 (en) 2014-07-02 2016-06-13 Specific biomarker set for non-invasive diagnosis of liver cancer

Country Status (13)

Country Link
EP (1) EP3164711A4 (en)
JP (2) JP2017520763A (en)
KR (1) KR102086788B1 (en)
CN (2) CN107478842B (en)
AU (2) AU2014399919B2 (en)
CA (1) CA2939912C (en)
HK (2) HK1224370A1 (en)
MY (2) MY179845A (en)
NZ (1) NZ722492A (en)
SG (1) SG11201606106SA (en)
TW (1) TWI700493B (en)
UY (1) UY36200A (en)
WO (1) WO2016003479A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106383231B (en) * 2016-09-02 2020-03-17 四川大学 Marker combination for diagnosing liver cancer and application thereof
GB201619954D0 (en) * 2016-11-25 2017-01-11 Oncimmune Ltd Antibody assay
KR102175265B1 (en) 2019-03-13 2020-11-06 충남대학교산학협력단 Biomarker composition comprising TXNDC7 for diagnosis or predicting prognosis of hepatocellular carcinoma
CN110646615B (en) * 2019-08-27 2021-07-13 南方医科大学 Biomarkers, therapeutic targets and uses of liver fibrosis
WO2023282916A1 (en) 2021-07-09 2023-01-12 Guardant Health, Inc. Methods of detecting genomic rearrangements using cell free nucleic acids
EP4407042A3 (en) 2020-07-10 2024-09-18 Guardant Health, Inc. Methods of detecting genomic rearrangements using cell free nucleic acids
CN113502328A (en) * 2021-05-27 2021-10-15 深圳市人民医院 Application of reagent for detecting expression level of marker in sample in preparation of kit for detecting or diagnosing breast cancer
CN113777295B (en) * 2021-09-15 2024-03-19 江南大学 High-sensitivity quantum dot probe for detecting tumor marker PD-L1, preparation method and application
CN113956344A (en) * 2021-10-14 2022-01-21 江南大学 Novel FGF analogue for treating liver cancer and application thereof
CN114113611B (en) * 2021-12-13 2023-07-14 郑州大学 A biomarker and detection kit for liver cancer diagnosis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6449562B1 (en) * 1996-10-10 2002-09-10 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and method
US6893844B1 (en) * 1998-09-22 2005-05-17 Long Yu DNA encoding a new human hepatoma derived growth factor and producing method thereof
US7387881B2 (en) * 2001-09-19 2008-06-17 The Regents Of The University Of Michigan Detection and treatment of cancers of the liver
AU2002361908A1 (en) * 2001-12-31 2003-07-24 Quark Biotech, Inc. Methods for identifying marker genes for cancer
GB0228900D0 (en) * 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
JP3960614B2 (en) * 2003-08-31 2007-08-15 株式会社イムノディア Anti-peptide antibody measurement method and vaccine candidate selection method for peptide vaccine
GB0406215D0 (en) * 2004-03-19 2004-04-21 Procure Therapeutics Ltd Prostate stem cell
EP1761648A1 (en) * 2004-06-18 2007-03-14 Roche Diagnostics GmbH Use of protein pdx1 as a marker for breast cancer
JP5211315B2 (en) * 2006-07-25 2013-06-12 国立大学法人愛媛大学 Tumor marker, tumor diagnostic kit, and method for measuring tumor marker
US20110281284A1 (en) * 2007-08-10 2011-11-17 Otsuka Pharmaceutical Co., Ltd Novel liver cancer marker
US8512963B2 (en) * 2009-11-25 2013-08-20 The Johns Hopkins University Detection and quantitation of full-length thioredoxin (TRX) and truncated thioredoxin (TRX 80) in complex samples
US9523680B2 (en) * 2010-06-30 2016-12-20 Ambergen, Inc. Global Proteomic screening of random bead arrays using mass spectrometry imaging
JP5493130B2 (en) * 2010-08-25 2014-05-14 国立大学法人山口大学 Autoantibody detection method
EP2678448A4 (en) * 2011-02-22 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L Circulating biomarkers
WO2013049704A2 (en) * 2011-09-28 2013-04-04 Armune Biosciences, Inc. Method and system of particle-phage epitope complex

Also Published As

Publication number Publication date
CN107478842A (en) 2017-12-15
AU2017232129B2 (en) 2018-10-25
CN105319362B (en) 2018-07-13
JP2020160082A (en) 2020-10-01
TWI700493B (en) 2020-08-01
WO2016003479A1 (en) 2016-01-07
AU2014399919B2 (en) 2019-10-24
CA2939912C (en) 2019-04-16
CN107478842B (en) 2020-10-16
CA2939912A1 (en) 2016-01-07
KR20170021234A (en) 2017-02-27
EP3164711A4 (en) 2018-05-23
TW201602579A (en) 2016-01-16
UY36200A (en) 2016-01-29
AU2017232129A1 (en) 2017-10-12
MY195045A (en) 2023-01-04
KR102086788B1 (en) 2020-03-09
MY179845A (en) 2020-11-18
AU2014399919A1 (en) 2016-08-11
JP2017520763A (en) 2017-07-27
EP3164711A1 (en) 2017-05-10
CN105319362A (en) 2016-02-10
HK1224370A1 (en) 2017-08-18
NZ722492A (en) 2019-09-27
SG11201606106SA (en) 2016-08-30

Similar Documents

Publication Publication Date Title
HUS2500001I1 (en) Antibody compositions for tumor treatment
SG10202011339RA (en) Microrna biomarker for the diagnosis of gastric cancer
ZA201701753B (en) Biomarkers for assessing breast cancer
HK1248803A1 (en) Specific biomarker set for non-invasive diagnosis of liver cancer
IL285077A (en) Compounds for treatment of cancer
SMT202100115T1 (en) Combinations of fgfr- and cmet-inhibitors for the treatment of cancer
GB201420859D0 (en) Tumour analysis
IL251376A0 (en) Methods for assessing risk of developing breast cancer
EP3227686A4 (en) Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer
HK1253082A1 (en) Method of diagnosis of breast cancer
SG11201701076TA (en) Diagnosis of cancer
EP3204008A4 (en) Use of biomarkers for predicting clinical sensitivity to cancer treatment
SG10201913528PA (en) Methods of diagnosing cancer
PL3152576T3 (en) Use of tm9sf4 as a biomarker for tumor associated exosomes
EP3189332A4 (en) Biomarkers for detection of breast cancer
GB201407837D0 (en) Methods of cancer therapy
IL248126A0 (en) Combination of cancer therapeutics
GB201410118D0 (en) Early diagnosis of leptospire
GB201414362D0 (en) Biomarkers for early diagnosis of ovarian cancer
ZA201704589B (en) Compounds for the treatment of cancer
GB201405286D0 (en) Cancer diagnostic
AU2014903898A0 (en) Methods for assessing the risk of developing breast cancer
GB201400387D0 (en) Diagnostic for gastric cancer
GB201411489D0 (en) Kit for diagnosis of foetal distress
AU2014901825A0 (en) Biomarker of Disease

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20240701